Differential levels of CHMP2B, LLPH, and SLC25A51 proteins in secondary renal amyloidosis. (2nd January 2021)

• Record Type: Journal Article
• Authors: Gupta, Nimisha; Sahar, Tahreem; Khowal, Sapna; Ganaie, Ishfaq Ahmad; Mughees, Mohd; Khullar, Dinesh; Jain, S. K.; Wajid, Saima
• Is Part Of: Expert review of proteomics. Volume 18:Number 1(2021)
• Page Start: 65
• Page End: 73
• Publication Date: 2021-01-02
• Subjects: 2D gel electrophoresis -- bio-layer interferometry -- serum biomarkers -- early diagnosis -- pathogenesis -- MALDI-TOF MS; Proteins -- Biotechnology -- Periodicals; Proteomics -- Periodicals; 572.6
• DOI: 10.1080/14789450.2021.1890588
• Languages: English
• ISSNs: 1478-9450

Abstract

ABSTRACT: Objectives: Renal amyloidosis (RA) is a rare disease, typically manifested with proteinuria, nephrotic syndrome, and ultimately leads to renal failure. The present study aims to profile the proteomes of renal amyloidosis patient's serum and healthy controls, along with relative quantification to find out robust markers for RA. Methods: In this study, 12 RA patients and their corresponding age and gender-matched healthy controls were recruited from the Nephrology department of Max Super Specialty Hospital, New Delhi. We employed gel-based proteomic approach coupled with MALDI-TOF MS to compare protein expression patterns in RA patients and controls. Furthermore, validation of differential proteins (selected) was done using bio-layer interferometry. Results: Eleven proteins showed remarkably altered expression levels. Moreover, expression modulation of three proteins (LLPH, SLC25A51, and CHMP2B) was validated which corroborated with two-dimensional gel electrophoresis (2-DE) results showing significant upregulation (p < 0.05) in RA patients followed by ROC analysis which demonstrated the diagnostic potential of these proteins. A protein-protein master network was generated implicating the above identified proteins along with their interactors, fishing out the routes leading to amyloidosis. Conclusion: This study indicates that the identified serum proteomic signatures could improve early diagnosis and lead to possible therapeutic targets in RA.